1515
Annons
BioStock: Pila Pharma initiates toxicological studies

Malmö company Pila Pharma is in full swing with preparations for a phase IIb study with the drug candidate XEN-D0501. But before the study can initiated, the company needs to conduct a three-month preclinical toxicological study. The company has now announced that the toxicological study has started. BioStock contacted Pila Pharma's CEO Dorte X Gram to find out more.

Read the full article at biostock.se:
https://www.biostock.se/en/2022/07/pila-pharma-initiates-toxicological-studies/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera